Evidence map›Paper›PMID 36915284›Full record

ArticleJournal of asthma and allergy2023

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.

Jonathan Corren, David J Jackson, Thomas B Casale, Larry Borish, Klaus F Rabe, William W Busse, Jorge F Maspero, Daniel J Jackson, Nadia Daizadeh, Arman Altincatal and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of asthma and allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414854 (A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02414854 phase3completednot on this map

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

TypeinterventionalSponsorSanofiRan2015 to 2017Enrolled1,902ConditionsAsthmaArmsDupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 4 countries.

Jonathan CorrenDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
David J JacksonKing's College London, London, UK.
Thomas B CasaleDivision of Allergy and Immunology, University of South Florida, Tampa, FL, USA.
Larry BorishAsthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA.
Klaus F RabeLungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany.ORCID 0000-0002-7020-1401
William W BusseUW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0003-2591-4696
Jorge F MasperoFundación CIDEA, Buenos Aires, Argentina.
Daniel J JacksonUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Nadia DaizadehSanofi, Cambridge, MA, USA.
Arman AltincatalSanofi, Cambridge, MA, USA.
Amr RadwanRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Angela KhodzhayevRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Michel DjandjiSanofi, Cambridge, MA, USA.
Juby A Jacob-NaraSanofi, Cambridge, MA, USA.
Paul J RoweSanofi, Bridgewater, NJ, USA.
Yamo DenizRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Sanofi (United States) · USRegeneron (United States) · USUniversity of Wisconsin–Madison · USFundación para la Investigación, Docencia y Prevención del Cáncer · ARGerman Center for Lung Research · DEUniversity of California, Los Angeles · USUniversity of South Florida · USUniversity of Virginia Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and improved pre-bronchodilator forced expiratory volume in 1 second (FEV Patients and Methods: Endpoints were annualized AER, change from baseline in pre-bronchodilator FEV Results: In all subgroups by number of allergens sensitized, dupilumab vs placebo reduced AER by 35-67% and improved both pre-bronchodilator FEV Conclusion: Dupilumab improved clinical outcomes and reduced biomarker levels in patients with uncontrolled, moderate-to-severe T2 asthma irrespective of allergen sensitization status or number. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02414854.

Indexed as

allergic asthmadupilumabperennial aeroallergentype 2 asthma

Identifiers

PMID36915284
PMCPMC10007984
OpenAlexW4323362312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.